{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:14:57Z","timestamp":1786994097823,"version":"build-2736575974"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.meegid.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,1,2]],"date-time":"2013-01-02T14:46:01Z","timestamp":1357137961000},"page":"247-257","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs"],"prefix":"10.1016","volume":"14","author":[{"given":"Yasir","family":"Waheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attya","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2012.12.004_b0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/13543784.2010.500285","article-title":"New NS5B polymerase inhibitors for hepatitis C","volume":"19","author":"Abravanel","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.meegid.2012.12.004_b0010","first-page":"390","article-title":"An evidence of high prevalence of hepatitis C virus in Faisalabad, Pakistan","volume":"28","author":"Ahmad","year":"2007","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.meegid.2012.12.004_b0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.micro.58.030603.123649","article-title":"Viral error catastrophe by mutagenic nucleosides","volume":"58","author":"Anderson","year":"2004","journal-title":"Annu. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.meegid.2012.12.004_b0020","first-page":"1333","article-title":"Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population","volume":"124","author":"Aziz","year":"2011","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.meegid.2012.12.004_b0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.meegid.2011.01.022","article-title":"Evaluation of prognostic factors for Peg interferon alfa-2b plus ribavirin treatment of HCV infected patients in Pakistan","volume":"11","author":"Aziz","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.meegid.2012.12.004_b0030","doi-asserted-by":"crossref","unstructured":"Aziz, H., Raza, A., Waheed, Y., Gill, U., Gill, M.L., 2012. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alpha 2a plus ribavirin in hepatitis C virus genotype 3 infected patients. Int. J. Infect. Dis. http:\/\/dx.doi.org\/10.1016\/j.ijid.2012.03.012.","DOI":"10.1016\/j.ijid.2012.03.012"},{"key":"10.1016\/j.meegid.2012.12.004_b0035","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1099\/0022-1317-81-7-1631","article-title":"Replication of hepatitis C virus","volume":"81","author":"Bartenschlager","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/095632020801900104","article-title":"Combinations of 2\u00a2-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system","volume":"19","author":"Bassit","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"15","author":"Behrens","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.meegid.2012.12.004_b0050","unstructured":"Bilello, J.P., Colla, M.L., Serra, I., Gillum, J.M., Soubasakos, M.A., Chapron, C., Li, B., Bonin, A., Panzo, R.J., Seifer, M., Standring, D.N. (downloaded july 2012) Enhance antiviral activity of IDX375, a novel HCV non-nucleoside inhibitor, in combination with other HCV antiviral agents in the genotype 1b replicon in vitro. Indenix Pharma, USA. pp. 192. <http:\/\/www.novirio.com\/hcv\/HCV2009%20IDX375.pdf>."},{"key":"10.1016\/j.meegid.2012.12.004_b0055","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1074\/jbc.M413410200","article-title":"Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors","volume":"280","author":"Biswal","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0060","first-page":"1026A","article-title":"Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in genotype 1 and 3 HCV-infected patients","volume":"50","author":"Brainard","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0065","doi-asserted-by":"crossref","first-page":"11580","DOI":"10.1128\/JVI.01519-10","article-title":"Hepatitis C virus RNA replication requires a conserved structural motif within the transmembrane domain of the NS5B RNA-dependent RNA polymerase","volume":"84","author":"Brass","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0075","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.meegid.2012.12.004_b0070","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/JVI.76.7.3482-3492.2002","article-title":"Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides","volume":"76","author":"Bressanelli","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0080","article-title":"First in human pharmacokinetics and antiviral activity of IDX375, a novel non nucleoside hepatitis c virus polymerase inhibitor","author":"Bruijne","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0085","first-page":"1565","article-title":"Mixed genotype infections with hepatitis C virus, Pakistan","volume":"17","author":"Butt","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.meegid.2012.12.004_b0090","series-title":"Viral Genome Replication","author":"Cameron","year":"2009"},{"key":"10.1016\/j.meegid.2012.12.004_b0095","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/JVI.76.8.3720-3730.2002","article-title":"Subcellular localization and topology of the p7 polypeptide of hepatitis C virus","volume":"76","author":"Carrere-Kremer","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0105","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/AAC.01032-08","article-title":"Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees","volume":"53","author":"Carroll","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0110","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"Chatterji","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0130","doi-asserted-by":"crossref","first-page":"20535","DOI":"10.1074\/jbc.M801490200","article-title":"A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase","volume":"283","author":"Chinnaswamy","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0115","first-page":"73","article-title":"An update on small molecule inhibitors of the HCV NS5B polymerase: effect on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies","volume":"2","author":"Chinnaswamy","year":"2010","journal-title":"Virus Adapt. Treat."},{"key":"10.1016\/j.meegid.2012.12.004_b0120","first-page":"21","article-title":"Conformations of the monomeric hepatitis C virus RNA dependent RNA polymerase","volume":"2","author":"Chinnaswamy","year":"2010","journal-title":"Virus Adapt. Treat."},{"key":"10.1016\/j.meegid.2012.12.004_b0125","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/JVI.02446-09","article-title":"Regulation of de novo-initiated RNA synthesis in hepatitis C virus RNA-dependent RNA polymerase by intermolecular interactions","volume":"84","author":"Chinnaswamy","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0135","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.4049\/jimmunol.174.4.2160","article-title":"Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway","volume":"174","author":"Chou","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.meegid.2012.12.004_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2009.03.015","article-title":"Evaluation of VCH-759 monotherapy in hepatitis C infection","volume":"51","author":"Cooper","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0145","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: direct molecular test by using ribavirin","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.meegid.2012.12.004_b0150","first-page":"25","article-title":"Robust antiviral efficacy of a \u201cfinger-loop\u201d allosteric inhibitor of the HCV polymerase in HCV infected chimpanzees","volume":"3","author":"DeFrancesco","year":"2007","journal-title":"Global Antiviral J."},{"key":"10.1016\/j.meegid.2012.12.004_b0155","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/AAC.00186-07","article-title":"Pyrophosphorylytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase","volume":"51","author":"Deval","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrg2323","article-title":"Rates of evolutionary change in viruses: patterns and determinants","volume":"9","author":"Duffy","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.meegid.2012.12.004_b0165","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/135965350901400104","article-title":"Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment","volume":"14","author":"Erhardt","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2012.12.004_b0175","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.meegid.2012.12.004_b0180","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/JVI.73.2.1649-1654.1999","article-title":"Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli","volume":"73","author":"Ferrari","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/mol.63.3.538","article-title":"Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets","volume":"63","author":"Gallois-Montbrun","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.meegid.2012.12.004_b0195","first-page":"S16","article-title":"Sustained virologic response (SVR) following RG7128 1500mg BID\/PEG-IFN\/RBV for 28 days in HCV genotype 2\/3 prior non-responders","volume":"52","author":"Gane","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0190","article-title":"Vertex QUAD therapy yielded 83\u201393% SVR with 12 weeks duration of therapy: VX222\/Telaprevir in combination with peginterferon alpha 2a and ribavirin in treatment na\u00efve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR 12 interim analysis","volume":"22","author":"Gane","year":"2012","journal-title":"APASL"},{"key":"10.1016\/j.meegid.2012.12.004_b0200","first-page":"1113","article-title":"Once daily GS-7977 plus ribavirin in HCV genotypes 1\u20133: the electron trial","volume":"47","author":"Gane","year":"2012","journal-title":"EASL"},{"key":"10.1016\/j.meegid.2012.12.004_b0205","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.meegid.2012.12.004_b0210","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0168-8278(07)62192-8","article-title":"GSK625433: a novel and highly potent inhibitor of the HCV NS5B polymerase","volume":"46","author":"Gray","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0215","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.24788","article-title":"Hepatitis c viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)","volume":"55","author":"Guedj","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0220","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1074\/jbc.M808889200","article-title":"Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus","volume":"284","author":"Hang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0225","doi-asserted-by":"crossref","first-page":"e39163","DOI":"10.1371\/journal.pone.0039163","article-title":"The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function","volume":"7","author":"Hebner","year":"2012","journal-title":"PLOS One"},{"key":"10.1016\/j.meegid.2012.12.004_b0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/135965350000500203","article-title":"Hepatitis C virus kinetics","volume":"5","author":"Herrmann","year":"2000","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2012.12.004_b0235","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/JVI.67.4.1953-1958.1993","article-title":"Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes","volume":"67","author":"Hijikata","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/viro.2001.0948","article-title":"A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase","volume":"285","author":"Hong","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.meegid.2012.12.004_b0245","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkin","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0250","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00238-08","article-title":"Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796","volume":"52","author":"Howe","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2334-8-69","article-title":"Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission","volume":"8","author":"Idrees","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.meegid.2012.12.004_b0260","unstructured":"Index Pharma. Downloaded 6th July, 2012. Drug discovery and development: IDX 184, a nucleoside\/tide polymerase inhibitor. <http:\/\/www.idenix.com\/hcv\/drug.html>."},{"key":"10.1016\/j.meegid.2012.12.004_b0275","doi-asserted-by":"crossref","first-page":"11121","DOI":"10.1128\/JVI.74.23.11121-11128.2000","article-title":"Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA dependent RNA polymerase","volume":"74","author":"Kao","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0270","doi-asserted-by":"crossref","DOI":"10.1007\/s11515-012-1188-0","article-title":"Assays for RNA synthesis and replication by the hepatitis C virus","author":"Kao","year":"2012","journal-title":"Front. Biol."},{"key":"10.1016\/j.meegid.2012.12.004_b0285","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analog. R1479 (4\u2032-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0290","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","article-title":"HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus","volume":"49","author":"Klumpp","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0280","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","article-title":"HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus","volume":"49","author":"Kneteman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0300","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1074\/jbc.M506407200","article-title":"Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase","volume":"280","author":"Kukolj","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0295","first-page":"08d","article-title":"Preclinical characterization of hepatitis C virus NS5B polymerase non-nucleosdie inhibitor BILB 1941","volume":"48","author":"Kukolj","year":"2011","journal-title":"EASL"},{"key":"10.1016\/j.meegid.2012.12.004_b0305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.meegid.2012.12.004_b0315","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(08)60068-9","article-title":"Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days","volume":"48","author":"Lalezari","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0310","first-page":"228A","article-title":"Antiviral activity, safety and pharmacokinetics of IDX184, a liver targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C","volume":"50","author":"Lalezari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0320","first-page":"1045A","article-title":"Combination of IDX184, a nucleotide prodrug polymerase inhibitor, with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro","volume":"50","author":"Lallos","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0325","first-page":"1044A","article-title":"BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C","volume":"50","author":"Larrey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2012.02.015","article-title":"Rapid and strong antiviral activity of the non-nucleoside NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 3a and ribavirin","volume":"57","author":"Larrey","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0335","doi-asserted-by":"crossref","first-page":"17117","DOI":"10.1074\/jbc.M111220200","article-title":"Bacteriophage phi 6 RNA-dependent RNA polymerase: molecular details of initiating nucleic acid synthesis without primer","volume":"277","author":"Laurila","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0340","first-page":"351","article-title":"Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase","volume":"4","author":"Lavie","year":"2004","journal-title":"Med. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0345","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0168-8278(09)60094-5","article-title":"Tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection","volume":"50","author":"Lawitz","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0350","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","article-title":"Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients","volume":"50","author":"Lawitz","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0360","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1128\/JVI.02628-05","article-title":"Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus","volume":"80","author":"Le Pogam","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0355","first-page":"1037A","article-title":"Combination therapy with nucleoside polymerase R7128 and protease R7227\/ITMN-191 inhibitors in genotype 1 HCV infected patients: interim resistance analysis of INFORM-1 cohorts A-D","volume":"50","author":"Le Pogam","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0365","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/13543784.2010.500285","article-title":"New NS5B polymerase inhibitors for hepatitis C","volume":"19","author":"Legrand-Abravanel","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.meegid.2012.12.004_b0265","series-title":"Safety and Tolerability of Filibuvir, a Non-nucleoside Inhibitor of HCV Polymerase","author":"Levin","year":"2009"},{"key":"10.1016\/j.meegid.2012.12.004_b0370","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vivo","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.meegid.2012.12.004_b0375","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0380","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/JVI.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity","volume":"71","author":"Lohmann","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0385","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.meegid.2012.12.004_b0390","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1074\/jbc.274.16.10807","article-title":"Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP","volume":"274","author":"Lohmann","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0395","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/AAC.01004-06","article-title":"Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759","volume":"51","author":"Lu","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0400","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/JVI.74.2.851-863.2000","article-title":"De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus","volume":"74","author":"Luo","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0410","unstructured":"Ma, H., Inocencio, N., Cruz, J.E., Cammack, N., Klumpp, K., 2009. Incorporation and chain termination efficiencies can differ between nucleoside inhibitors of HCV replication at initiation and elongation phases: identification of a potential additional mechanism of action of R1479-TP. In: Presented at the 16th International Symposium on Hepatitis C Virus and Related Viruses, 2009, Nice, France."},{"key":"10.1016\/j.meegid.2012.12.004_b0415","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.01172-07","article-title":"Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand","volume":"52","author":"Magee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0420","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.1128\/JVI.74.20.9532-9539.2000","article-title":"3\u2032-azido-3\u2032- deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1","volume":"74","author":"Mansky","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0425","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0430","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevie with peginterferon and ribavirin for chronic HCV genotpe 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.meegid.2012.12.004_b0435","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/jm1013105","article-title":"Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino) ethyl] amino}-7,8-dihydro-6H-indolo [1,2-e][1,5] benzoxazocine-11- carboxylic acid (MK-3281), a potent and orally bioavailable finger loop inhibitor of the hepatitis C virus NS5B polymerase","volume":"54","author":"Narjes","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0440","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.meegid.2012.12.004_b0445","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1099\/vir.0.79967-0","article-title":"Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver","volume":"85","author":"Nielsen","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0455","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1128\/JVI.73.9.7694-7702.1999","article-title":"A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA","volume":"73","author":"Oh","year":"1999","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.meegid.2012.12.004_b0460","first-page":"872","volume":"54","author":"Ohara","year":"2011","journal-title":"Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice"},{"key":"10.1016\/j.meegid.2012.12.004_b0450","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/viro.1998.9463","article-title":"Analysis of RNA-Dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure","volume":"252","author":"O\u2019Reilly","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.meegid.2012.12.004_b0465","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1089-3261(02)00065-X","article-title":"Hepatitis C virus genetic variability: pathogenic and clinical implications","volume":"7","author":"Pawlotsky","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.meegid.2012.12.004_b0470","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0475","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1081\/NCN-200060112","article-title":"Nm 283, an efficient prodrug of the potent anti-HCV agent 2\u00a2-C-methylcytidine","volume":"24","author":"Pierra","year":"2005","journal-title":"Nucleos. Nucleot. Nucleic Acids"},{"key":"10.1016\/j.meegid.2012.12.004_b0480","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0485","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2174\/092986706779010270","article-title":"Prodrug approaches of nucleotides and oligonucleotides","volume":"13","author":"Poijarvi-Virta","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0495","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 Infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.meegid.2012.12.004_b0490","article-title":"ABT-072 or ABT-333 combined with Pegylated Interferon\/Ribavirin after 3 day monotherapy in HCV genotype 1 infected treatment na\u00efve subjects: 12 weeks sustained virological response (SVR) and safety results","volume":"47","author":"Poordad","year":"2012","journal-title":"EASL"},{"key":"10.1016\/j.meegid.2012.12.004_b0500","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/v2102169","article-title":"Inhibitors of the Hepatitis C virus RNA-dependent RNA polymerase NS5B","volume":"2","author":"Powdrill","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2012.12.004_b0505","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","first-page":"293","article-title":"Biochemical Activities of the HCV NS5B RNA Dependent RNA Polymerase","author":"Ranjith-Kumar","year":"2006"},{"key":"10.1016\/j.meegid.2012.12.004_b0510","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1261\/rna.2163106","article-title":"Recombinant viral RdRps can initiate RNA synthesis from circular templates","volume":"12","author":"Ranjith-Kumar","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.meegid.2012.12.004_b0515","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1128\/JVI.75.18.8615-8623.2001","article-title":"Terminal nucleotidyl transferase activity of recombinant Flaviviridae RNA-dependent RNA polymerases: implication for viral RNA synthesis","volume":"75","author":"Ranjith-Kumar","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0520","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1128\/JVI.76.24.12526-12536.2002","article-title":"Requirements for de novo initiation of RNA synthesis by recombinant flaviviral RNA-dependent RNA polymerases","volume":"76","author":"Ranjith-Kumar","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0525","doi-asserted-by":"crossref","first-page":"e22575","DOI":"10.1371\/journal.pone.0022575","article-title":"A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A","volume":"6","author":"Ranjith-Kumar","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.meegid.2012.12.004_b0530","first-page":"55","article-title":"Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties","volume":"242","author":"Reed","year":"1999","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.meegid.2012.12.004_b0535","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0540","first-page":"5A","article-title":"Treatment naive, HCV genotype 1-infected subjects show significantly greater decrease when treated for 28 days of ABT-333 plus peginterferon and ribavirin than peginterferon and ribavirin alone","volume":"50","author":"Rodrigues-Torres","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0545","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60033-5","article-title":"Safety and antiviral activity of the non-nucleoside polymerase inhibitor VX-222 in treatment na\u00efve genotype 1 HCV infected patients","volume":"52","author":"Rodriguez-Torres","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0550","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Trans. Med."},{"key":"10.1016\/j.meegid.2012.12.004_b0555","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.virol.2008.10.030","article-title":"Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro","volume":"384","author":"Rubach","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.meegid.2012.12.004_b0560","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2478\/abm-2010-0032","article-title":"Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan","volume":"4","author":"Safi","year":"2010","journal-title":"Asian Biomed."},{"key":"10.1016\/j.meegid.2012.12.004_b0565","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.meegid.2012.12.004_b0570","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.meegid.2012.12.004_b0575","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.01599-08","article-title":"Preclinical characterization of PF- 00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"53","author":"Shi","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0580","first-page":"859A","article-title":"Mechanistic characterization of GS-9190, a novel non nucleoside inhibitor of the hcv NS5B polymerase with potent antiviral activity and a unique mechanism of action","volume":"46","author":"Shih","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0585","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1128\/JVI.01008-09","article-title":"Structural and functional analysis of hepatitis C virus strain JFH1 polymerase","volume":"83","author":"Simister","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0590","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1006\/bbrc.2000.2120","article-title":"De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase","volume":"268","author":"Sun","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.meegid.2012.12.004_b0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.meegid.2011.10.009","article-title":"An overview: in vitro models of HCV replication in different cell cultures","volume":"12","author":"Tariq","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.meegid.2012.12.004_b0600","doi-asserted-by":"crossref","first-page":"34218","DOI":"10.1074\/jbc.M806797200","article-title":"Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase","volume":"283","author":"Tchesnokov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0605","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/JVI.78.2.938-946.2004","article-title":"Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides","volume":"78","author":"Tomei","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/095632020501600403","article-title":"HCV antiviral resistance. The impact of in vitro studies on the development of anitiviral agents targeting the viral NS5B polymerase","volume":"16","author":"Tomei","year":"2005","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines","volume":"140","author":"Traut","year":"1994","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.meegid.2012.12.004_b0625","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.05611-11","article-title":"Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus infected patients","volume":"56","author":"Troke","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0630","unstructured":"Vertex Pharma., 2012. Vertex announces 12week on treatment data and SCR4 from phase 2 study of interferon free treatment regimen of INCIVEK, VX 222 and ribavirin in people with Genotype 1 hepatitis C. (accessed 16.07.12), <http:\/\/investors.vrtx.com\/releasedetail.cfm?releaseid=650944>."},{"key":"10.1016\/j.meegid.2012.12.004_b0635","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(07)61648-1","article-title":"Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alpha-2b in tratment naive patients with chronic HCV","volume":"56","author":"Villano","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0640","first-page":"855A","article-title":"GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants","volume":"46","author":"Vliegen","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0645","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/S0168-8278(09)60972-7","article-title":"Preclinical characterization of ABT-072: a novel non-nucleoside HCV polymerase inhibitor","volume":"50","author":"Wagner","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0655","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3748\/wjg.15.5647","article-title":"Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors","volume":"15","author":"Waheed","year":"2009","journal-title":"World J. Gasteroenterol."},{"issue":"9","key":"10.1016\/j.meegid.2012.12.004_b0660","first-page":"e6142","article-title":"Development of global consensus sequence and analysis of highly conserved domains of HCV NS5B protein","volume":"12","author":"Waheed","year":"2012","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.meegid.2012.12.004_b0650","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.meegid.2012.12.004_b0665","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1128\/JVI.76.8.3865-3872.2002","article-title":"Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase","volume":"76","author":"Wang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0670","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.meegid.2012.12.004_b0675","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2012.03.025","article-title":"Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a and 6a","volume":"429","author":"Wong","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.meegid.2012.12.004_b0680","doi-asserted-by":"crossref","first-page":"15479","DOI":"10.1074\/jbc.273.25.15479","article-title":"RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region","volume":"273","author":"Yamashita","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.meegid.2012.12.004_b0685","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/pro.5560070402","article-title":"Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form","volume":"7","author":"Yan","year":"1998","journal-title":"Protein Sci."},{"key":"10.1016\/j.meegid.2012.12.004_b0690","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.05438-11","article-title":"Biochemical study of the comparative inhibition of Hepatitis C virus RNA polymerase by VX-222 and Filibuvir","volume":"56","author":"Yi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2012.12.004_b0695","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/hep.1840380413","article-title":"Identification of a ribavirin resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy","volume":"38","author":"Young","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2012.12.004_b0700","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/S0168-8278(10)61035-5","article-title":"Combination of two complementary nucletide analogues PSI-7977 and PSI-938 effectively clears wild type and NS5B S282T HCV replicons comparison with combination of other antiviral compounds","volume":"52","author":"Zennou","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2012.12.004_b0705","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Heptology"},{"key":"10.1016\/j.meegid.2012.12.004_b0715","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/JVI.74.4.2017-2022.2000","article-title":"De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase","volume":"74","author":"Zhong","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2012.12.004_b0710","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vivo","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134812003863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134812003863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:45:29Z","timestamp":1687934729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134812003863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":141,"alternative-id":["S1567134812003863"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2012.12.004","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}